BlackRock Amends Neurocrine Biosciences Stake (SC 13G/A)
Ticker: NBIX · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 914475
| Field | Detail |
|---|---|
| Company | Neurocrine Biosciences Inc (NBIX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock just updated its Neurocrine Biosciences stake, signaling a potential shift in institutional sentiment.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating a change in its ownership of Neurocrine Biosciences Inc. common stock as of December 31, 2023. This filing, Amendment No. 12, updates their previous disclosures regarding their passive investment in the biotechnology company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal shifts in their confidence or investment strategy for Neurocrine Biosciences, potentially influencing other investors.
Why It Matters
This filing shows BlackRock, a major institutional investor, updated its stake in Neurocrine Biosciences, which can influence market perception and investor confidence in the stock.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate significant risk.
Analyst Insight
An investor should note BlackRock's continued involvement as a passive holder, but this filing alone doesn't suggest a strong buy or sell signal. It's a routine update reflecting their position as of December 31, 2023.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- NEUROCRINE BIOSCIENCES INC (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 12 (number) — the specific amendment number of this filing
Forward-Looking Statements
- BlackRock will continue to hold a significant, but passive, stake in Neurocrine Biosciences Inc. (BlackRock Inc.) — high confidence, target: Q2 2024
- The updated filing will not cause a significant immediate price movement in Neurocrine Biosciences stock. (NEUROCRINE BIOSCIENCES INC) — high confidence, target: January 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a major institutional investment manager.
What is the subject company whose securities are being reported?
The subject company is NEUROCRINE BIOSCIENCES INC, identified by CIK 0000914475 and CUSIP 64125C109.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023.
What is the business address of the reporting person, BlackRock Inc.?
BlackRock Inc.'s business address is 50 HUDSON YARDS, NEW YORK, NY 10001.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding NEUROCRINE BIOSCIENCES INC (NBIX).